NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Everfront Biotech Inc.

Everfront Biotech Inc.

Private
TaipeiHealthcare & Life Scienceshttps://www.efbiotech.com/

Last Round

IPO

Jan 3, 2025

Total Funding Raised

$9.58M

Company Overview

Everfront Biotech Inc. is a biotechnology company that develops orphan drugs for hard-to-treat diseases such as glioblastoma, pancreatic cancer, and amyotrophic lateral sclerosis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

orphan drugsdrug delivery systembiopharmaceuticalsustained-releaseglioblastoma treatmentsmall-molecule therapeuticsclinical-stage biotechimplantable drug deliveryoncology R&Ddrug licensingneurodegenerative diseasebiotech startupdrug pipelinetherapeutic candidate

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Everfront Biotech Inc. Comparables

Compare Everfront Biotech Inc. with similar companies based on industry and business-model similarity.

Everfront Biotech Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeOnc Technologies Holdings, Inc.
83%
Eisai
82%
NanOlogy, LLC
77%

Everfront Biotech Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJan 3, 2025
Convertible DebtJul 12, 2023
GrantSep 1, 2017
GrantDec 1, 2014
GrantMay 1, 2013

Everfront Biotech Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 3, 2025

    $10M raised with ROTH Capital Partners and others.

  • Jul 12, 2023

    Raised $8M in convertible debt.

Everfront Biotech Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Everfront Biotech Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Everfront Biotech Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersTaipei
Year Founded2010
Last FundingJan 3, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.